

**Erratum**

Reaven GM. The metabolic syndrome: is this diagnosis necessary? *Am J Clin Nutr* 2006;83:1237–47.

In Table 6 (page 1243), the references cited should read from 83 through 101, rather than from 82 through 100.

**Erratum**

Hallberg L, Hulthen L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. *Am J Clin Nutr* 2000;71:1147–60.

The correct equation for adjusting for iron status (Equation 11) should be as follows:

$$\text{Iron absorption (mg)} = \text{iron absorption (alg mg)} \times (23/\text{SF})^{0.94049} \quad (1)$$

Additionally, the correct equation for calculating the expected iron absorption ration set when calcium is present (Equation 5) should read as follows:

$$0.4081 + (0.5919/1 + 10^{-[2.022 - \log(\text{Ca}+1)] \times 2.919}) \quad (2)$$

**Erratum**

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006;84:18–28.

A sentence in the abstract begins “An intake for all adults of  $\geq 1000$  IU (40  $\mu\text{g}$ ) vitamin D...” The value for vitamin D should be 25  $\mu\text{g}$ , not 40  $\mu\text{g}$ .



## The metabolic syndrome: is this diagnosis necessary?<sup>1,2</sup>

Gerald M Reaven

### ABSTRACT

Values of insulin-mediated glucose disposal vary continuously throughout a population of apparently healthy persons, and a difference of  $\geq 600\%$  exists between the most insulin-sensitive and the most insulin-resistant persons. Approximately 50% of this variability can be attributed to differences in adiposity (25%) and fitness (25%), with the remaining 50% likely of genetic origin. The more insulin-resistant a person, the more likely that he or she will develop some degree of glucose intolerance, high triacylglycerol and low HDL concentrations, essential hypertension, and procoagulant and proinflammatory states, all of which increase the risk of cardiovascular disease (CVD). To identify persons at greater CVD risk because of these abnormalities, the World Health Organization, the Adult Treatment Panel III, and the International Diabetes Federation created a new diagnostic category, the metabolic syndrome. Although the components of the 3 versions of the metabolic syndrome are similar, the specific values for those components that define an abnormality are somewhat different, and the manner in which the abnormalities are used to make a positive diagnosis varies dramatically from version to version. This review will summarize the similarities in and differences between the 3 versions of the metabolic syndrome, point out that the clustering of components that make up all 3 definitions of the metabolic syndrome is not accidental and occurs only in insulin-resistant persons, develop the argument that diagnosing the metabolic syndrome in a person has neither pedagogical nor clinical utility, and suggest that the clinical emphasis should be on treating effectively any CVD risk factor that is present. *Am J Clin Nutr* 2006;83:1237–47.

**KEY WORDS** Metabolic syndrome, insulin resistance, cardiovascular disease

### INTRODUCTION

In today's climate of full disclosure, I should state at the beginning that I have published several articles (1–4) critical of the effort to create a diagnostic category of the metabolic syndrome, and that I believe that this effort has little clinical or pedagogic utility and even can do more harm than good. Although the 3 published versions of the metabolic syndrome are conceptually different (5–8), the reservation expressed above applies to all of these definitions. If there is anything useful to be accomplished by creating such a diagnostic category, I believe that the approach of the World Health Organization (WHO) was the most rational effort (5), and the recent version (8) of the International Diabetes Federation (IDF) was the most dangerous.

Although a major focus of the review will be on the physiologic and clinical utility of making a diagnosis of metabolic

syndrome, it is equally important to differentiate between the metabolic syndrome and a construct that (1) might be best designated as insulin resistance syndrome. In the former instance, the goal is to develop criteria by which to “diagnose” the metabolic syndrome, and, in the latter instance, the goal is to increase the understanding of the relation between resistance to insulin-mediated glucose uptake (IMGU) and a variety of related abnormalities and clinical syndromes. Although the 2 notions are frequently considered interchangeable, the concepts are quite different, and this review is focused entirely on the metabolic syndrome.

### THE MANY FACES OF THE METABOLIC SYNDROME

In a document whose primary purpose was to update the classification and diagnostic criteria of diabetes mellitus, the WHO was the first organization to outline clinical criteria (**Table 1**) for diagnosing the metabolic syndrome (5). In this context, the WHO designated the metabolic syndrome as a special classification for persons with the potential for diabetes (manifested as having impaired glucose tolerance, impaired fasting glucose, or insulin resistance by hyperinsulinemic euglycemic clamp). The WHO felt that, once these persons developed certain cardiovascular disease (CVD) risk components, those components combined into a unique clinical entity, and the patients should be considered to have the metabolic syndrome. Aside from glucose tolerance status and insulin resistance, risk components deemed useful in identifying persons with metabolic syndrome included central obesity, dyslipidemia, hypertension, and microalbuminuria. The WHO stated that each component conveyed greater CVD risk but that, when combined, the components became more “powerful.” Therefore, the reason for diagnosing the metabolic syndrome was to identify persons at undue risk of CVD.

The Adult Treatment Panel III (ATP III) released its definition of the metabolic syndrome in 2001 (6). The goal of the ATP III was somewhat different from that of the WHO, in that the ATP III was focused less on type 2 diabetes and more on CVD risk. Within that context, an additional aim was to “focus on primary prevention in persons with multiple risk factors.” To address this second aim, the ATP III considered the metabolic syndrome to

<sup>1</sup> From the Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA.

<sup>2</sup> Reprints not available. Address correspondence to GM Reaven, Division of Cardiovascular Medicine, Falk CVRC, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305. E-mail: greaven@cvmed.stanford.edu.

Received December 19, 2005.

Accepted for publication March 8, 2006.



**TABLE 1**  
World Health Organization definition of the metabolic syndrome<sup>1</sup>

The patient must have 1 of the following:
Diabetes mellitus
Fasting plasma glucose $\geq 7$ mmol/L (126 mg/dL) or 2-h postglucose load $\geq 11.1$ mmol/L (200 mg/dL)
Impaired glucose tolerance
Fasting plasma glucose $< 7$ mmol/L (126 mg/dL) and 2-h postglucose load $\geq 7.8$ mmol/L (140 mg/dL) and $< 11.1$ mmol/L (200 mg/dL)
Impaired fasting glucose
Fasting plasma glucose $\geq 6.1$ mmol/L (110 mg/dL) and $< 7$ mmol/L (126 mg/dL) and (if measured) 2-h postglucose load $< 7.8$ mmol/L (140 mg/dL)
Insulin resistance
Glucose uptake below lowest quartile for background population under investigation under hyperinsulinemic, euglycemic conditions
Plus any 2 of the following:
Waist-to-hip ratio $> 0.9$ in men, $> 0.85$ in women; BMI $> 30$ ; or both
Triacylglycerols $\geq 1.7$ mmol/L (150 mg/dL); HDL cholesterol $< 0.9$ mmol/L (35 mg/dL) in men, $< 1.0$ mmol/L (39 mg/dL) in women; or both
Blood pressure $\geq 140/90$ mm Hg (revised from $\geq 160/90$ mm Hg)
Microalbuminuria (urinary albumin excretion rate $\geq 20$ $\mu$ g/min or albumin-to-creatinine ratio $\geq 30$ mg/g)

<sup>1</sup> Adapted from reference 5.

represent “multiple, interrelated factors that raise CVD risk” and stated that the root causes were overweight or obesity, physical inactivity, and genetic factors. The specific factors considered important were abdominal obesity, atherogenic dyslipidemia, high blood pressure, glucose intolerance, and prothrombotic and proinflammatory states. The panel believed that the syndrome increased CVD risk at any given LDL-cholesterol concentration and that it should be a secondary target of therapy in cholesterol management. The ATP III definition of the metabolic syndrome is shown in **Table 2**.

The most recent version of the metabolic syndrome was the result of a consensus conference organized by the IDF that involved 21 participants invited from Europe, North and South American, Asia, Africa, and Australia. After the meeting, this group published the IDF’s new worldwide definition of the metabolic syndrome, which laid out a “consensus on a ‘platinum standard’ definition, which highlights additional metabolic criteria which should be measured in all research conducted in this field from this point onwards” (7). The components that make up the diagnostic criteria for the IDF version of the the metabolic syndrome are seen in **Table 3**.

**TABLE 2**  
Adult Treatment Panel III definition of the metabolic syndrome<sup>1</sup>

Any 3 of following:
Fasting glucose $\geq 6.1$ mmol/L (110 mg/dL)
Waist circumference
Men: $> 102$ cm (40 in)
Women: $> 88$ cm (35 in)
Triacylglycerols $\geq 1.7$ mmol/L (150 mg/dL)
HDL cholesterol
Men: $< 1.036$ mmol/L (40 mg/dL)
Women: $< 1.295$ mmol/L (50 mg/dL)
Blood pressure $\geq 130/85$ mm Hg

<sup>1</sup> Adapted from reference 6.

**TABLE 3**  
International Diabetes Federation definition of the metabolic syndrome<sup>1</sup>

The patient must have 1 of the following:
Diabetes mellitus
Fasting plasma glucose $\geq 7$ mmol/L (126 mg/dL) or 2-h postglucose load $\geq 11.1$ mmol/L (200 mg/dL)
Impaired glucose tolerance
Fasting plasma glucose $< 7$ mmol/L (126 mg/dL) and 2-h postglucose load $\geq 7.8$ mmol/L (140 mg/dL) and $< 11.1$ mmol/L (200 mg/dL)
Impaired fasting glucose
Fasting plasma glucose $\geq 6.1$ mmol/L (110 mg/dL) and $< 7$ mmol/L (126 mg/dL) and (if measured) 2-h postglucose load $< 7.8$ mmol/L (140 mg/dL)
Insulin resistance
Glucose uptake below lowest quartile for background population under investigation under hyperinsulinemic, euglycemic conditions
Plus any 2 of the following:
Waist-to-hip ratio $> 0.9$ in men, $> 0.85$ in women; BMI $> 30$ ; or both
Triacylglycerols $\geq 1.7$ mmol/L (150 mg/dL); HDL cholesterol $< 0.9$ mmol/L (35 mg/dL) in men, $< 1.0$ mmol/L (39 mg/dL) in women; or both
Blood pressure $\geq 140/90$ mm Hg (revised from $\geq 160/90$ mm Hg)
Microalbuminuria (urinary albumin excretion rate $\geq 20$ $\mu$ g/min or albumin-to-creatinine ratio $\geq 30$ mg/g)

It is apparent from a comparison of Tables 1, 2, and 3 that only minor differences exist between the specific components that make up the 3 versions of the metabolic syndrome. Furthermore, the versions share one major characteristic—neither the individual components selected to serve as criteria nor the specific cutoffs are the result of prospective studies. Instead, they represent the collective wisdom or prejudices (or both) of “experts” selected by whoever was organizing the “consensus” conference. The appropriateness of this process is not the focus of this chapter, but it seems necessary to address this issue here.

Of greater pedagogic and clinical importance are 2 fundamental differences between the 3 diagnostic schemes. One major point of departure is the manner in which the various criteria are organized. The ATP III criteria are not distinguished qualitatively from each other, and a combination of any 3 of the 5 criteria is viewed as having the same adverse effect as any other group of 3 abnormalities. I assume this decision is based on the thought expressed in a recent joint statement from the American Heart Association and the National Heart, Lung, and Blood Institute that there is no common “cause” of the metabolic syndrome (8). This important issue will be discussed below, but at this point suffice it to say that both the WHO and the IDF take a different approach, in that they insist that one essential criterion be met. The similarity between the 2 positions ends at this point, with the WHO requiring that there be evidence of insulin resistance but the IDF’s fundamental criterion for a diagnosis of metabolic syndrome is an ethnicity-adjusted degree of abdominal obesity.

The other major difference between the 3 definitions of the metabolic syndrome has to do with the role of excess adiposity. The WHO considers it to be an ancillary criteria (Table 1) and can be satisfied by either a certain level of overall obesity, as assessed by body mass index (BMI), or an excessive waist-to-hip ratio, as an index of abdominal obesity. For the ATP III, excess adiposity is one of the 5 equally important criteria that can be used to diagnose metabolic syndrome (Table 2), but in this case can only be met by exceeding a sex-specific value of waist circumference (WC). The status of WC has been further elevated in the IDF version of the metabolic syndrome (Table 3), and it is now the one

criterion that must be fulfilled for a diagnosis of the metabolic syndrome.

### DOES THE METABOLIC SYNDROME HAVE A COMMON “CAUSE”?

When the components that make up the 3 versions of the metabolic syndrome are compared, it is paradoxical to see how similar they are and how disparate are the ways in which they are used to diagnose metabolic syndrome. In the case of the WHO, abnormal values for blood pressure, urinary albumin excretion, and triacylglycerol and HDL-cholesterol concentrations will determine whether an insulin-resistant person has or does not have metabolic syndrome. In the case of the IDF definition, even if a person displayed all of these abnormalities and had type 2 diabetes in addition, he or she would not have the metabolic syndrome if the WC was not large enough. The ATP III version of the metabolic syndrome is the most democratic; there is no hierarchical relation between the 5 components, and any combination of 3 will do. The lack on the part of the ATP III of assigning any priority to the 5 components of the metabolic may be a reflection of the panel's view that the cluster of abnormalities “probably has more than one cause” (6, 8). It is difficult to disagree with the conclusion that the related abnormalities that make up all 3 versions of metabolic have more than one cause. For example, it is obvious there are many potential reasons for elevated blood pressures. At the same time, one must ask whether the fact that any of the criteria used to diagnose the metabolic syndrome may develop for more than one reason means that there cannot be a *common* physiologic event that greatly increases the likelihood that a person will undergo the changes that can lead to a diagnosis of metabolic syndrome. I propose that the answer to this rhetorical question should be “no,” and, moreover, that the clustering of abnormalities that make up all 3 versions of the metabolic syndrome does not evolve accidentally, and that a defect in insulin action plays a fundamental role in the development of the CVD risk factors that make up all versions of the metabolic syndrome.

#### Glucose intolerance

The prevalence of some degree of abnormal glucose tolerance or type 2 diabetes (or both)—one of the criteria in all 3 definitions of the metabolic syndrome—is the abnormality most closely related to insulin resistance. Indeed, > 60 y ago, Himsworth and Kerr (9) challenged the conventional wisdom that “all cases of human diabetes could be explained by deficiency of insulin,” proposed that “a state of diabetes might result from inefficient action of insulin as well as from a lack of insulin,” and stated, “the diminished ability of the tissues to utilize glucose is referable either to a deficiency of insulin or to insensitivity to insulin, although it is possible that both factors may operate simultaneously.” In the same vein, Himsworth (10) suggested in 1949 that “we should accustom ourselves to the idea that a primary deficiency of insulin is only one, and then not the commonest, cause of the diabetes syndrome.” It is now appreciated that insulin resistance is a common characteristic of patients with type 2 diabetes (11–16) and that insulin resistance (or hyperinsulinemia as a surrogate estimate of insulin resistance) is a powerful and independent predictor of type 2 diabetes (17–21). Finally, the greater the degree of insulin resistance, the higher the plasma glucose response to oral glucose in persons with normal oral

**TABLE 4**

Relation between insulin resistance and plasma triacylglycerol concentrations<sup>1</sup>

---



---



---

glucose tolerance (22). Thus, an enormous amount of evidence documents a very close relation between insulin resistance and abnormal elevations in plasma glucose concentrations.

Finally, it should be emphasized that nondiabetic persons with relatively minor degrees of glucose intolerance also have higher blood pressures and the dyslipidemic changes—high triacylglycerol and low HDL-cholesterol concentrations—that make up the remaining metabolic criteria of all 3 definitions of the metabolic syndrome (23–26)

#### Dyslipidemia

It has been known for > 30 y that there is a highly significant relation between insulin resistance, compensatory hyperinsulinemia, and hypertriglyceridemia (27, 28). It is now apparent that the link between insulin resistance or hyperinsulinemia and dyslipidemia is a much broader one, which is not limited to an increase in plasma triacylglycerol concentrations. Thus, although the various definitions of metabolic syndrome have selected the combination of high plasma triacylglycerol and low HDL-cholesterol concentrations as a diagnostic criterion, it is clear that these changes are also associated with a decrease in LDL particle size (small, dense LDL) and the postprandial accumulation of triacylglycerol-rich remnant lipoproteins (29). Not only are all of these changes significantly associated with insulin resistance or hyperinsulinemia (27–33), but each one has also been shown to increase the risk of CVD (34–39).

#### Plasma triacylglycerol concentrations

The relations outlined in **Table 4** are based on the results of 2 published studies (28, 40). Table 4 depicts the relation among insulin resistance, plasma insulin response, hepatic VLDL-triacylglycerol synthesis and secretion, and plasma triacylglycerol concentrations in nondiabetic persons (28) whose baseline plasma triacylglycerol concentrations range from 69 to 546 mg/dL; the table also describes the same relations in persons with plasma triacylglycerol concentrations < 175 mg/dL (40). Implicit in these findings is the view that the major cause of elevated plasma triacylglycerol concentrations in nondiabetic persons is an increase in hepatic VLDL-triacylglycerol secretion rate, secondary to insulin resistance and the resultant hyperinsulinemia. These data provide a quantitative estimate of the close relation between insulin resistance, compensatory hyperinsulinemia, hepatic VLDL-triacylglycerol secretion, and plasma triacylglycerol concentrations in apparently healthy persons.

### *Postprandial lipemia*

The higher is the fasting triacylglycerol concentration, the greater will be the postprandial accumulation of triacylglycerol-rich lipoproteins (ie, VLDL, chylomicron remnants, and VLDL remnants) in nondiabetic persons (41). Both the relation between fasting triacylglycerol concentration and postprandial lipemia and the daylong increases in triacylglycerol-rich lipoproteins in nondiabetic persons are significantly correlated with the magnitude of the insulin resistance and compensatory hyperinsulinemia (32, 33, 42). Although the postprandial elevation of triacylglycerol-rich lipoproteins is related to the fasting triacylglycerol concentration, postprandial lipemia is also enhanced when insulin-resistant or hyperinsulinemic persons are matched by degree of fasting hypertriglyceridemia with persons from an insulin-sensitive population (43).

### *HDL cholesterol*

Increases in plasma VLDL-triacylglycerol concentration are usually associated with low HDL-cholesterol concentrations, and it appears that insulin resistance and compensatory hyperinsulinemia are independently associated with both of these changes (30). Low HDL-cholesterol concentrations in insulin-resistant or hyperinsulinemic persons are partly due to the transfer, which is catalyzed by cholesteryl ester transfer protein, of cholesterol from HDL to VLDL (44); the higher the VLDL pool size, the greater the transfer rate from HDL to VLDL and the lower the resulting HDL-cholesterol concentration. The fractional catabolic rate of apoprotein A-I is increased in patients with primary hypertriglyceridemia (45), hypertension (46), and type 2 diabetes (47). In type 2 diabetes, it has been shown that the greater the degree of hyperinsulinemia, the lower the HDL-cholesterol concentration (47). Evidence also exists that, in nondiabetic persons, the higher the fractional catabolic rate of apoprotein A-I, the lower the HDL-cholesterol concentration (48), and that these changes are associated with increases in plasma insulin concentrations

### *LDL particle diameter*

Analysis of LDL particle size distribution (35) has identified multiple distinct LDL subclasses, and it appears that LDL particles in most persons can be characterized by a predominance of larger LDL (diameter:  $> 255 \text{ \AA}$ ; pattern A) or smaller LDL (diameter:  $< 255 \text{ \AA}$ ; pattern B). Persons with pattern B LDL have higher plasma triacylglycerol and lower HDL-cholesterol concentrations than do persons with pattern A LDL. Not surprisingly, healthy volunteers with small, dense LDL particles (pattern B) are relatively insulin resistant, glucose intolerant, hyperinsulinemic, hypertensive, and hypertriglyceridemic, and they have low HDL-cholesterol concentrations (31).

### *Atherogenic lipoproteins and insulin resistance*

The evidence discussed above provides strong support for the conclusion that the lipoprotein abnormalities that are part of all 3 definitions of the metabolic syndrome are more likely to occur together and are significantly associated with insulin resistance and compensatory hyperinsulinemia. However, not all persons with these abnormalities are insulin resistant. A high fasting plasma triacylglycerol concentration and hyperchylomicronemia can occur in persons who have a primary defect in the catabolism of triacylglycerol-rich lipoproteins (ie, fat-induced

lipemia; 49). Furthermore, not all insulin-resistant persons will develop the atherogenic lipoprotein profile associated with the defect in insulin action. On the other hand, insulin resistance or hyperinsulinemia is the only physiologic abnormality that can lead to the clustering of abnormalities that includes the atherogenic lipoprotein profile discussed above, as well as increases in plasma glucose concentration and blood pressure.

### **Blood pressure**

The relation between insulin resistance, elevated blood pressure, and CVD is more complicated than that of any of the other components that make up the various definition of metabolic syndrome. There is substantial evidence for the following 3 findings linking insulin resistance and hyperinsulinemia to essential hypertension. First, patients with essential hypertension, as a group, are insulin resistant and hyperinsulinemic (50–52). Second, normotensive first-degree relatives of patients with essential hypertension are more insulin resistant and hyperinsulinemic than are matched control subjects without a family history of hypertension (53–55). Third, hyperinsulinemia, as a surrogate estimate of insulin resistance, has been shown in population-based studies to predict the eventual development of essential hypertension (56–59).

In contrast, probably no more than 50% of patients with essential hypertension are insulin resistant (60). However, it is patients with essential hypertension who are insulin resistant or hyperinsulinemic who have the other components of the various definitions of metabolic syndrome and are therefore at greatest risk of CVD. For example, patients with essential hypertension and electrocardiographic evidence of myocardial ischemia are insulin resistant, somewhat glucose intolerant, and hyperinsulinemic and have high triacylglycerol and low HDL-cholesterol concentrations compared with a normotensive control group or patients with essential hypertension whose electrocardiograms are entirely normal (61). Direct evidence of the link between the dyslipidemia present in insulin-resistant or hyperinsulinemic patients with essential hypertension and CVD comes from the results of the Copenhagen Male Study (62), in which 2906 participants were divided into 3 groups according to their fasting plasma triacylglycerol and HDL-cholesterol concentrations. Men whose plasma triacylglycerol and HDL-cholesterol concentrations were in the upper or lower third, respectively, of the whole population, were assigned to the high-triacylglycerol–low-HDL-cholesterol group. At the other extreme, a low-triacylglycerol–high-HDL-cholesterol group was composed of those persons whose plasma triacylglycerol and HDL-cholesterol concentrations were in the lower and upper thirds, respectively, of the study population for these 2 lipid measurements. The intermediate group consisted of those participants whose lipid values did not qualify them for either of the 2 extreme groups. The results of this prospective study indicated that CVD risk was not increased in patients with hypertension in the absence of high triacylglycerol and low HDL-cholesterol concentrations, and the group at greatest risk was made up of those persons with high blood pressure and high triacylglycerol and low HDL-cholesterol concentrations.

In summary, insulin-resistant or hyperinsulinemic persons are more likely to develop essential hypertension, hypertension is a well-recognized CVD risk factor, and patients with essential hypertension and high triacylglycerol and low HDL-cholesterol concentrations are at greatest risk of CVD. If high blood pressure



**TABLE 5**Simple and partial correlations for PAI-1 in normotensive volunteers<sup>1</sup>


---



---



---



---



---



---



---



---

is one of the criteria for the metabolic syndrome, there is little doubt that its association with the other components can only be attributed to the concomitant presence of insulin resistance or hyperinsulinemia.

#### **Insulin resistance and procoagulant and proinflammatory factors**

Although measures of procoagulant or proinflammatory factors have not been elevated to the status of diagnostic criteria, definitions of the metabolic, all comment on their relation with the cluster of abnormalities that make up the definition. The association between insulin resistance and hyperinsulinemia, elevated concentrations of plasminogen activator inhibitor-1, and CVD have been known for some time (63, 64). Of greater relevance to this review are the data in **Table 5** showing that concentrations of plasminogen activator inhibitor-1 in a group of apparently healthy persons was significantly correlated with degree of insulin resistance (as quantified by steady-state plasma glucose concentrations during the insulin suppression test), and fasting plasma insulin, triacylglycerol, and HDL cholesterol concentrations (65). Thus, variations in concentrations of plasminogen activator inhibitor-1 cluster with insulin resistance or compensatory hyperinsulinemia, and the dyslipidemia characteristic of the defect in insulin action.

The proinflammatory factor currently attracting the most attention as indicating increased CVD risk is C-reactive protein, but there is a much longer history of a relation between an increase in white cell count and heart disease. Indeed, data from the Women's Health Initiative Observational Study suggest that a high white cell count was comparable in magnitude to increases in concentrations of C-reactive protein as a predictor of CVD risk (66). Evidence of a relation between white cell counts and insulin resistance or compensatory hyperinsulinemia was published several years ago (67); the evidence indicated that the higher the white cell count, the more insulin resistant a person ( $r = 0.50$ ,  $P > 0.001$ ), the greater ( $P < 0.001$ ) the person's plasma glucose ( $r = 0.48$ ) and insulin ( $r = 0.50$ ) responses to an oral glucose challenge, the higher the person's triacylglycerol concentration ( $r = 0.37$ ), and the lower the person's HDL-cholesterol concentration ( $r = -0.38$ ,  $P > 0.005$ ). However, there was no significant relation between the white cell count and either age or BMI.

The relations described in this section provide evidence that the additional CVD risk factors considered to be present in patients diagnosed as having metabolic syndrome are significantly related to both insulin resistance and hyperinsulinemia, as well as to the other components of the metabolic syndrome. These observations provide further support for the view that insulin resistance or hyperinsulinemia provides a coherent explanation for how all of these individual variables cluster together.

#### **EXCESS ADIPOSITY, INSULIN RESISTANCE, AND THE METABOLIC SYNDROME**

Evidence was marshaled in the preceding section that insulin resistance or hyperinsulinemia was the one factor that could explain the clustering of diagnostic criteria for the different versions of the metabolic syndrome. Implicit in this view is that the adiposity criteria that appear in all metabolic syndrome definitions are qualitatively different from any of the other components listed in Tables 1–3. Specifically, dyslipidemia (high triacylglycerol and low HDL-cholesterol concentrations), hyperglycemia, and hypertension are independent factors that directly increase the risk of CVD (34, 36, 68, 69), whereas the relation between excess adiposity and CVD risk is different. For example, substantial numbers of overweight or obese persons do not have the abnormalities outlined above (70, 71). The components of the metabolic syndrome occur more commonly in overweight or obese persons, but this relation is not due to obesity, per se, but rather to the fact that excess adiposity increases the likelihood that a person will be insulin resistant (70, 71). This point of view receives support from the results of the recent study of Ninomiya et al (72), which showed that abdominal obesity, as defined by the ATP III, was the only criterion not statistically associated with the development of either CVD or stroke in an analysis of the data from the third National Health and Nutrition Examination Survey (NHANES III). The authors suggested that this finding “may reflect an indirect effect of high WC through other components of the syndrome,” and this formulation will be pursued below.

#### **Obesity and insulin-mediated glucose uptake**

The European Group for the Study of Insulin Resistance analyzed the results of euglycemic, hyperinsulinemic clamp studies

in 1146 nondiabetic, normotensive volunteers and found that only  $\approx 25\%$  of the obese volunteers were classified as being insulin-resistant according to the criteria used (73). These authors also pointed out that differences in WC were unrelated to insulin sensitivity after adjustment for age, sex, and BMI. Results similar to those of the European Group for the Study of Insulin Resistance have been published by investigators at Stanford University (70, 71); in those studies, differences in the degree of obesity accounted for approximately one-third of the variability of insulin-mediated glucose uptake (IMGU) in apparently healthy persons. Those studies did not take into consideration the fact that the more physically fit a person is, the more insulin sensitive he or she will be (74) or that differences in degree of physical fitness are approximately as powerful as differences in adiposity in modulation of IMGU (75). Thus, differences in adiposity modulate insulin action, but adiposity is only one of the variables determining whether a person is sufficiently insulin resistant to develop an adverse clinical outcome.

#### **Waist circumference compared with body mass index as a predictor of insulin-mediated glucose uptake**

Because BMI and WC are highly correlated, it is not obvious on an a priori basis that WC is a superior predictor of the adverse effects of excess adiposity, let alone that it is considered the essential diagnostic criterion in the IDF version of the metabolic syndrome. For example, measurements obtained from  $\approx 15\,000$  participants in NHANES III indicated that the correlation coefficient between BMI and WC was  $> 0.9$  irrespective of the age, sex, or ethnicity of groups evaluated (76). Given these findings, it was not surprising that the correlation coefficient between degree of adiposity and insulin resistance was the same ( $r = 0.6$ ) in apparently healthy persons, irrespective of whether BMI or WC was used as the index of obesity (77). As in NHANES III, BMI and WC were also highly correlated ( $r = 0.9$ ). Because the relation between IMGU and overall obesity (BMI) does not differ significantly from that between IMGU and abdominal obesity (WC), it seems that either index of adiposity is equally predictive of differences in insulin action.

#### **Relation between adiposity, insulin resistance, and risk of cardiovascular disease**

Rates of IMGU vary by  $>600\%$  in apparently healthy persons, and, because the distribution of these values is continuous (78), there is no objective way to classify a person as insulin-resistant. However, prospective studies exist that can serve as the basis for an operational definition. With the use of the magnitude of the insulin response to oral glucose as a surrogate maker of insulin resistance, 25% of an apparently healthy population with the highest insulin concentrations is at a significantly greater risk of CVD (79). According to the results of 2 prospective studies in which the insulin suppression test was used to quantify IMGU at baseline (80, 81), the third of the population that was the most insulin resistant (ie, those with the highest steady-state plasma glucose concentrations) was at significantly greater risk of CVD than was the population third that was the most insulin sensitive (ie, those with the lowest steady-state plasma glucose concentrations). Thus, for the purposes of this discussion, the third of the population with the highest steady-state plasma glucose concentrations will be operationally defined as insulin-resistant, and the third with the lowest steady-state plasma glucose concentrations will be defined as insulin-sensitive.

#### **Prevalence of insulin resistance as a function of body mass index**

When 465 apparently healthy persons were divided into tertiles of IMGU according to their BMI (82), a large majority ( $\approx 66\%$ ) of the normal-weight persons (BMI:  $< 25.0$ ) were in the most insulin-sensitive tertile, whereas the other third of the insulin-sensitive persons were either overweight or obese. Furthermore, approximately two-thirds of those in the insulin-resistant tertile were either normal-weight or overweight, and only about one-third of the most insulin-resistant persons were actually obese (BMI: 30–35). These data provide further evidence that, in general, the heavier the person, the more likely he or she is to be insulin resistant, but that obesity does not necessarily equal insulin resistance.

#### **WHAT ABOUT VISCERAL OBESITY?**

Evidence presented to this point has shown that measurements of BMI and WC are highly correlated, that they are associated with a specific measure of IMGU to an identical degree, and that not all overweight or obese persons are insulin resistant. These conclusions are at odds with the conventional wisdom that overweight or obesity is synonymous with insulin resistance and with the notion, codified by the ATP III (6) and the view of the IDF (7), that abdominal obesity is the source of all metabolic “evil.” One possible explanation for this discrepant opinion of the importance of abdominal obesity in the genesis of insulin resistance and its consequences is the failure to take into consideration the importance of visceral obesity, and this issue will be addressed next.

#### **Visceral obesity and insulin resistance**

The results of 19 studies (22 comparisons; 83–101) that have quantified the magnitude of the relation between IMGU and various estimates of adiposity, including visceral obesity (or visceral fat, VF), in nondiabetic subjects are shown in **Table 6**. The studies are listed in chronological order, and the following inclusion criteria were used to construct the table: imaging techniques were used to quantify the various fat depots; IMGU had to be quantified with specific, not surrogate estimates; and the actual experimental data had to be available, before the use of arbitrary “adjustments” or multiple regression analysis. Space constraints prohibit a complete discussion of possible differences in both the imaging techniques used in individual studies and the specific methods used to quantify IMGU.

Perhaps the simplest conclusion to be drawn from the results in **Table 6** is that correlation coefficients ( $r$  values) between VF and IMGU are usually  $< 0.6$ , values that are no greater than the relation between IMGU and either BMI or WC, as shown previously (70, 71). Indeed,  $r$  values between IMGU and VF varied from 0.4 to 0.6 in 18 of the 21 measurements in **Table 7**, and differences in VF accounted for  $\approx 25\%$  of the variability in IMGU in most instances.

Second, although the relation between BMI and IMGU was analyzed in only 4 studies (85, 93, 97, 99), the correlation coefficients in those instances were comparable to the values for the relation between IMGU and VF. That relation was compared more often than was that between IMGU and total fat, but, when both fat depots were evaluated, it appeared that the 2 estimates of adiposity provided  $r$  values of similar magnitude. If anything, the relation of total fat and



TABLE 6

Correlation coefficients (*r*) between insulin-mediated glucose uptake and body fat distribution<sup>1</sup>

Reference	Population	VF	SF	TF	BMI <sup>2</sup>
82	39 men	-0.51	-0.62	-0.61	
83	60 subjects	-0.50	-0.50	-0.57	
84	26 obese subjects	-0.56		-0.54	-0.55
85	54 subjects	-0.52	-0.61	-0.58	
86	20 South Asian men	-0.59	-0.54	-0.56	
87	47 men	-0.61	-0.53		
88	27 postmenopausal women	-0.39	-0.43	-0.30	
89	44 obese postmenopausal women	-0.40	-0.17		
90	68 white children	-0.59	-0.70	-0.68	
	51 African American children	-0.43	-0.47	-0.52	
91	55 postmenopausal women	-0.49	-0.43		
92	48 subjects	-0.58	-0.41		-0.52
93	24 subjects	-0.55	-0.47	-0.61	
94	89 obese males	-0.41			
95	40 obese premenopausal women	-0.34	-0.06		
96	174 subjects	-0.69	-0.57		-0.63
97	32 Hispanic children	-0.44	-0.46	-0.46	
98	39 men	-0.71			-0.56
99	44 African American men	-0.57	-0.57		
	35 African American women	-0.50	-0.67		
100	11 Thai women	-0.60	-0.47	-0.38	
	11 Thai men	-0.54	-0.45	-0.80	

<sup>1</sup> VF, visceral fat; SF, subcutaneous (abdominal) fat; TF, total fat.<sup>2</sup> Measured as kg/m<sup>2</sup>.

IMGU was somewhat greater in 8 of the 12 comparisons than was that of VF and IMGU (83, 84, 86, 91, 94, 98, 101).

The emphasis in the studies listed in Table 6 was a on comparison of the relation between IMGU and subcutaneous abdominal fat (SF) with the relation between IMGU and VF, and the magnitude of the 2 relations seems reasonably comparable. Although there are 2 examples in which the relation between IMGU and SF was quite different from that between IMGU and VF (89, 95), the *r* values in the remaining 17 available comparisons between IMGU and VF or SF did not vary a great deal: in 8 instances, they were somewhat higher with VF (87, 88, 92–94, 97, 101), in 7 instances, they were higher with SF (83, 86, 90, 91, 98, 100), and on 2 occasions, they were identical (84, 100).

The data in Table 6 do not show a uniquely close relation between VF and IMGU, which contrasts with the relation between insulin sensitivity and BMI, SF, or total fat. This conclusion should not be too surprising in view of a study whose results showed that, “independent of age and sex, the combination of

BMI and WC explained a greater variance in nonabdominal, abdominal, subcutaneous, and visceral fat than [did] either BMI or WC alone” (102).

### Visceral fat and adverse clinical outcomes

Although the data presented in Table 6 do not identify a unique relation between either WC or VF and IMGU, abdominal obesity could still be particularly useful in identifying persons at increased risk of clinical syndromes related to insulin resistance. For example, there are many reports emphasizing the relation between IMGU and abdominal obesity in general or VF specifically as a predictor of the development of the clinical syndromes related to insulin resistance (103–108). At the same time, other studies have come to a somewhat different conclusion. For example, in Pima Indians, increases in visceral obesity did not correlate with decreases in IMGU (109), and BMI was the estimate of adiposity with the highest hazard ratio in the prediction of type 2 diabetes (110). Furthermore, adding WC to that study's model did not improve its predictive ability. Results of a prospective study of Mexican Americans (111) indicated that persons with the highest baseline plasma glucose and insulin values were most likely to develop type 2 diabetes, independent of differences in age, BMI, or central obesity. In addition, a prospective study in a predominantly white population concluded that “both overall and abdominal adiposity strongly and independently predict risk of type 2 diabetes” (112). Moreover, studies in several ethnic groups have shown that BMI was as good as if not better than abdominal obesity as a predictor of high blood pressure and the dyslipidemia of insulin resistance (113–115). The clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension described in both whites and African Americans was most strongly related to insulin concentration, although the magnitude decreased after adjustment for differences in BMI and

TABLE 7

“Diagnosing” the metabolic syndrome in 3 men of European ancestry<sup>1</sup>

Variable	Patient A (WHO)	Patient B (ATP)	Patient C (IDF)
Age (y)	54	54	54
Waist circumference (cm)	93	93	93
FPG (mg/dL)	107	103	187
Triacylglycerol (mg/dL)	197	157	197
HDL cholesterol (mg/dL)	30	45	30
Blood pressure (mm Hg)	145/95 <sup>2</sup>	135/90	145/95
Metabolic syndrome	No	Yes	No

<sup>1</sup> FPG, fasting plasma glucose; WHO, World Health Organization; ATP, Adult Treatment Panel III; IDF, International Diabetes Federation.

<sup>2</sup> Systolic/diastolic (all such values).





abdominal obesity (116) In this latter instance, it was concluded that all 3 variables—insulin concentration, abdominal girth, and BMI—contributed to the adverse consequences of insulin resistance. Thus, although WC may be a powerful predictor of clinical outcomes linked to insulin resistance, considerable evidence also exists that overall obesity, as estimated by BMI, not only contributes to insulin resistance but also increases the likelihood that a person will develop the clinical syndromes associated with the defect in insulin action.

### METABOLIC SYNDROME: CLINICAL UTILITY OR FUTILITY?

The goal of diagnosing the metabolic syndrome is to identify persons at increased risk of CVD. Because each component that makes up the versions of the metabolic syndrome increases CVD risk (34, 36, 37, 62, 68, 69), it seems prudent to treat any of these abnormalities that are present. Furthermore, it would not be too surprising that the more abnormalities present in any given person, the greater would be his or her risk of CVD. The question can be raised, however, as to whether identifying a person as having metabolic syndrome necessarily indicates that he or she is at greater risk of CVD than is a person who may not qualify for that designation. This did not seem to be the case when the ATP III criteria were applied to the Framingham Study database (117); a recent report pointed out that persons meeting any 2 criteria were at no less risk than were those meeting 3 criteria. Indeed, it would be possible to describe a number of prototypic clinical situations in which a person with 1 or 2 abnormalities would be at greater risk of CVD than would a patient who met the metabolic syndrome diagnostic criteria. For example, a 54-y-old man of European ethnicity, with a WC of 93 cm and plasma glucose and triacylglycerol concentrations of 203 and 193 mg/dL, respectively, does not have the metabolic syndrome according to the IDF criteria. If that patient is compared with another European male, who meets the IDF criteria for the metabolic syndrome by virtue of having a WC of 94 cm and elevated plasma glucose (103 mg/dL) and triacylglycerol (155 mg/dL) concentrations, is there any doubt that the first patient, with frank type 2 diabetes and a greater degree of hypertriglyceridemia but without the metabolic syndrome, is at greater risk of CVD than is the second patient, who does have the metabolic syndrome?

Another confounding clinical issue relates to the fundamental philosophical differences between the 3 definitions of the metabolic syndrome. This dilemma is exemplified by the clinical data in Table 7, in which 3 different men of European ancestry are classified by the 3 different versions of the metabolic syndrome. If the WHO criteria are applied to patient A, the plasma glucose concentration is not high enough to meet the essential criterion of insulin resistance. Thus, unless an oral-glucose-tolerance test or a euglycemic clamp study is performed, this patient does not have metabolic syndrome according to the WHO criteria. At the same time, in light of his plasma triacylglycerol (197 mg/dL) and HDL-cholesterol (30 mg/dL) concentrations and his blood pressure (145/95), is there any doubt that he is at increased risk of CVD?


Patient B has the metabolic syndrome according to the ATP III diagnostic criteria because he exceeds the glucose, triacylglycerol, and blood pressure cutoffs. The modest elevations of plasma glucose and triacylglycerol concentrations, along with the minimal increase in blood pressure, may well place this person at

greater risk of CVD. However, if his triacylglycerol concentration were 147 mg/dL instead of 157 mg/dL, and if his glucose concentration were 153 mg/d rather than 103 mg/dL, he would no longer have the metabolic syndrome but would be at much greater risk of CVD.

Patient C has type 2 diabetes and is at the greatest risk of CVD because he has the characteristic dyslipidemia of insulin resistance and is hypertensive, although his WC is not large enough to merit the diagnosis of metabolic syndrome. A diagnosis of type 2 diabetes is one of the components of all 3 definitions of the metabolic syndrome. However, irrespective of the version of the metabolic syndrome that is being used, it is possible to have type 2 diabetes and not have the metabolic syndrome. Patient C falls into that category. Once the diagnosis of type 2 diabetes has been made, clinical guidelines outlining treatment approaches to all of the abnormalities present in patients with type 2 diabetes are available (118). Do we need 2 diagnostic categories—type 2 diabetes patients with and without metabolic syndrome?

It is obvious that, by juggling the clinical findings in Table 7, it is possible to create an almost infinite number of scenarios in which persons who do not meet the diagnostic criteria for metabolic syndrome would be at greater risk of CVD than would those who do. Given this situation, it seems difficult to maintain that a diagnosis of metabolic syndrome provides unique clinical information.

### CONCLUSION

IMGU varies by 600% to 800% in apparently healthy persons, and the third of this population that is the most insulin resistant is at a much greater risk of several abnormalities and clinical syndromes, including type 2 diabetes and CVD. Differences in degree of adiposity (25%) and level of physical fitness (25%) explain approximately half of the variability in insulin action, and the remaining 50% is most likely related to genetic differences. Although the 3 versions of the metabolic syndrome contain essentially identical components, they differ profoundly in the philosophical basis underlying their approach to a positive diagnosis. On the basis of the considerations discussed in this review, it is argued that there are multiple reasons to question the pedagogic utility of making diagnoses of metabolic syndrome. From a clinical standpoint, I subscribe to the guidelines outlined in the recent joint report from the American Diabetes Association and the European Association for the Study of Diabetes (119): 1) providers should avoid labeling patients with the term *metabolic syndrome*; 2) adults with any major CVD risk factor should be evaluated for the presence of other CVD risk factors; and 3) all CVD risk factors should be individually and aggressively treated. If these goals are achieved, there is no longer a need for a diagnosis of metabolic syndrome, a controversy about the best definition of the metabolic syndrome, or any confusion as to the clinical approach to patients who, although they are at greater risk of CVD, do not qualify for a diagnosis of metabolic syndrome. 

The author had no personal or financial conflict of interest.

### REFERENCES

1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. *Endocrinol Metab Clin North Am* 2004;33:283–303.
2. Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. *Diabetes Vasc Dis Res* 2004;1:68–76.



3. Reaven GM. The metabolic syndrome: requiescat in pace. *Clin Chem* 2005;51:931-8.
4. Reaven GM. Counterpoint: Just being alive is not good enough. *Clin Chem* 51:1354-7.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-53.
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
7. The IDF consensus worldwide definition of the metabolic syndrome. Part 1. Worldwide definition for use in clinical practice. Internet: [www.idf.org](http://www.idf.org) (accessed 28 July 2005).
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Curr Opin Cardiol* 2006;21:1-6.
9. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. *Clin Sci* 1939;4:119-52.
10. Himsworth HP. The syndrome of diabetes mellitus and its causes. *Lancet* 1949;1:465-73.
11. Shen S-W, Reaven GM, Farquhar JW. Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. *J Clin Invest* 1970;49:2151-60.
12. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. *J Clin Invest* 1975;55:454-61.
13. Kimmerling G, Javorski WC, Olefsky JM, Reaven GM. Locating the site(s) of insulin resistance in patients with nonketotic diabetes mellitus. *Diabetes* 1976;25:673-8.
14. DeFronzo R, Deibert D, Hendler R, Felig P, Soman V. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. *J Clin Invest* 1979;63:939-46.
15. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. *J Clin Invest* 1981;68:957-69.
16. Reaven GM. Insulin resistance in non-insulin-dependent diabetes mellitus. Does it exist and can it be measured? *Am J Med* 1983;74:3-17.
17. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 yr. *Diabetes* 1987;36:179-86.
18. Saad MF, Pettit DJ, Mott DM, Knowler WC, Nelson RG, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. *Lancet* 1989;1:1356-9.
19. Haffner SM, Stern MP, Mitchell BD, Hazua HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body-fat distribution. *Diabetes* 1990;39:283-8.
20. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:1988-92.
21. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of the diabetic parents. *Ann Intern Med* 1990;113:909-12.
22. Reaven GM, Brand RJ, Chen Y-DI, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. *Diabetes* 1993;42:1224-32.
23. Zavaroni I, Dall'Aglio E, Bonora E, Alpi O, Passeri M, Reaven GM. Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. *Am J Med* 1987;83:609-12.
24. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595-607.
25. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. *N Engl J Med* 1989;320:702-6.
26. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA* 1990;263:2893-8.
27. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. *J Clin Invest* 1967;46:1756-67.
28. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. *Am J Med* 1974;57:551-60.
29. Reaven GM. The insulin resistance syndrome. *Curr Atheroscler Rep* 2003;5:364-71.
30. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. *J Intern Med* 1992;231:25-30.
31. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. *J Clin Invest* 1993;92:141-6.
32. Jeppesen J, Hollenbeck CB, Zhou M-Y, et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. *Arterioscler Thromb Vasc Biol* 1995;15:320-4.
33. Abbasi F, McLaughlin T, Lamendola C, et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. *J Clin Endocrinol Metab* 1999;84:3903-6.
34. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. *Circulation* 1977;55:767-72.
35. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WS, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA* 1988;260:1917-21.
36. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment. *Circulation* 1992;85:37-45.
37. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). *Am J Cardiol* 1992;70:733-7.
38. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. *Arterioscler Thromb* 1992;12:1336-45.
39. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia: studies in men with previous myocardial infarction at young age. *Arterioscler Thromb* 1993;13:11-22.
40. Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. *Metabolism* 1981;30:165-71.
41. Nestel PJ. Relationship between plasma triglycerides and removal of chylomicrons. *J Clin Invest* 1964;43:943-9.
42. Kim H-S, Abbasi F, Lamendola C, McLaughlin T, Reaven GM. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. *Am J Clin Nutr* 2001;74:592-5.
43. Chen Y-DI, Swami S, Skowronski R, Coulston AM, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 76:172-7.
44. Swenson TL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. *Diabetes Metab Rev* 1991;7:139-53.
45. Fidge N, Nestel P, Ishikawa T, et al. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. *Metabolism* 1980;29:643-53.
46. Chen Y-DI, Sheu WH-H, Swislocki ALM, Reaven GM. High density lipoprotein turnover in patients with hypertension. *Hypertension* 1991;17:386-93.
47. Golay A, Zech L, Shi M-Z, Chiou, Y-AM, Reaven GM, Chen Y-DI. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. *J Clin Endocrinol Metab* 1987;65:512-8.
48. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. *Arterioscler Thromb* 1994;14:707-20.
49. Steiner G. Lipoprotein lipase in fat-induced hyperlipemia. *N Engl J Med* 1968;279:70-4.
50. Ferrannini E, Buzzigoli G, Bonadonna R. Insulin resistance in essential hypertension. *N Engl J Med* 1987;317:350-7.
51. Shen D-C, Shieh S-M, Fuh M, Wu D-A, Chen Y-DI, Reaven GM.



- Resistance to insulin-stimulated glucose uptake in patients with hypertension. *J Clin Endocrinol Metab* 1988;66:580-3.
52. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance, and hyperinsulinemia in patients with hypertension. *Am J Hypertens* 1989;2:419-23.
  53. Ferrari P, Weidmann P, Shaw S, et al. Altered Insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent. *Am J Med* 1991;91:589-96.
  54. Facchini F, Chen Y-DI, Clinkingbeard C, Jeppesen J, Reaven GM. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. *Am J Hypertens* 1992;5:694-9.
  55. Allemann Y, Horber FF, Colombo M, et al. Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. *Lancet* 1993;341:327-31.
  56. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. *J Hypertension* 1991;9:217-23.
  57. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. *Hypertension* 1992;20:797-801.
  58. Taittonen L, Uhari M, Nuutinen M, Turtinen J, Pokka T, Akerblom HK. Insulin and blood pressure among healthy children. *Am J Hypertens* 1996;9:193-9.
  59. Raitakari OT, Porkka KVK, Rönnemaa T, et al. The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study. *Diabetologia* 1995;38:1042-50.
  60. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. *J Intern Med* 1992;231:235-40.
  61. Sheuh WH-H, Jeng C-Y, Shieh S-M, et al. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. *Am J Hypertens* 1992;5:444-8.
  62. Jeppesen J, Hein HO, Suadcani P, Gynterberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. *Arch Intern Med* 2001;16:361-6.
  63. Hamsten A, Wiman B, Defaire U, Blombäck M. Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. *N Engl J Med* 1985;313:1557-63.
  64. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. *Diabetologia* 1991;34:457-62.
  65. Abbasi F, McLaughlin T, Lamendola C, Lipinska I, Tofler G, Reaven GM. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women. *Arterioscler Thromb Vasc Biol* 1999;19:2818-21.
  66. Margolis KL, Manson JF, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. *Arch Intern Med* 2005;165:500-8.
  67. Facchini F, Hollenbeck CB, Chen YN, Chen YD, Reaven GM. Demonstration of a relationship between white blood cell count, insulin resistance, and several risk factors for coronary heart disease in women. *J Intern Med* 1992;232:267-72.
  68. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC report. *JAMA* 2003;289:2560-72.
  69. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. *Diabetes Care* 1979;1979;2:131-41.
  70. Abbasi F, Brown BWB, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease. *J Amer Coll Card* 2002;40:937-43.
  71. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven GM. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann Intern Med* 2003;139:802-9.
  72. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen R. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third National Health and Nutrition Examination Survey. *Circulation* 2004;109:42-6.
  73. Ferrannini E, Natali A, Bell P, Cavallo-Perin, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. *J Clin Invest* 1997;100:1166-73.
  74. Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven GM. Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. *Diabetes* 1983;32:408-11.
  75. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in man. *Am J Physiol* 1985;248(3 Pt 11):E286-91.
  76. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. *Obes Res* 2003;11:1223-31.
  77. Farin HMF, Abbasi F, Reaven GM. Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. *Metabolism* 2005;54:1323-8.
  78. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. *Diabetes Care* 2000;23:171-5.
  79. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla Factory revisited. *Metabolism* 1999;48:989-94.
  80. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. *J Clin Endocrinol Metab* 1998;83:2773-6.
  81. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. *J Clin Endocrinol Metab* 2001;86:3574-8.
  82. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. *Metabolism* 2004;53:495-9.
  83. Abate N, Garg A, Peshock RM, Stray-Gunderson J, Grundy S. Relationships of generalized and regional adiposity to insulin sensitivity in man. *J Clin Invest* 1995;96:88-98.
  84. Cefalu WT, Wang ZQ, Werbel S, et al. Contribution of visceral fat to the insulin resistance of aging. *Metabolism* 1995;44:954-9.
  85. Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Veiio R. Visceral adipose tissue impairs insulin secretion and sensitivity, but not energy expenditure in obesity. *Metabolism* 1997;46:123-9.
  86. Goodpaster BH, Thaete JA, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. *Diabetes* 1997;46:1579-85.
  87. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin and insulin resistance in Asian Indian Men. *J Clin Endocrinol Metab* 1999;84:137-44.
  88. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal tissue and insulin resistance. *Am J Physiol Endocrinol Metab* 2000;278:E941-8.
  89. Sites CK, Calles-Escandon J, Brochu M, Butterfield M, Ashikaga T, Poehlman ET. Relation of regional fat distribution to insulin sensitivity in postmenopausal women. *Fertil Steril* 2000;73:61-5.
  90. Brochu M, Starling RD, Tchernof A, Mathews DE, Garcia-Rubi E, Poehlman ET. Visceral adipose tissue is an independent correlate of glucose disposal in older postmenopausal women. *J Clin Endocrinol Metab* 2001;85:2378-84.
  91. Goran MI, Bergman RN, Gower BA. Influence of total vs. visceral fat on insulin action and secretion in African American and white children. *Obes Res* 2001;9:423-31.
  92. Rendell M, Hulthen UL, Tornquist C, Groop L, Mattiason I. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. *J Clin Endocrinol Metab* 2001;86:744-9.
  93. Purnell JQ, Kahn SE, Schwartz RS, Brunzell JD. Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with combined hyperlipidemia. *Arterioscler Thromb Vasc Biol* 2001;21:567-72.
  94. Raji A, Seeley EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and caucasians. *J Clin Endocrinol Metab* 2001;86:5366-71.
  95. Ross R, Aru J, Freman J, Hudson R, Janssen I. Abdominal obesity and insulin resistance in obese men. *Am J Physiol Endocrinol Metab* 2002;282:E657-63.
  96. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition and insulin resistant in premenopausal women. *J Clin Endocrinol Metab* 2002;87:5044-51.



97. Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations. *Diabetes* 2002;51:1005–15.
98. Cruz ML, Bergman RN, Goran MI. Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. *Diabetes Care* 2002;25:1631–6.
99. Gan SK, Krikeos AD, Poynten AM, et al. Insulin action, regional fat, and myocyte lipid; altered relationships with increased adiposity. *Obes Res* 2003;11:1295–305.
100. Tulloch-Reid MK, Hanson RL, Sebring NG, et al. Both subcutaneous and visceral adipose tissues correlate highly with insulin resistance in African Americans. *Obes Res* 2004;12:1352–9.
101. Rattarasarn C, Leelawattan R, Soonthornpun S, Setasuban W, Thamprasit A. Gender differences of regional abdominal fat distribution and their relationships with insulin sensitivity in healthy and glucose-intolerant Thais. *J Clin Endocrinol Metab* 2004;89:6266–70.
102. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal, subcutaneous, and visceral fat. *Am J Clin Nutr* 2002;75:683–8.
103. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* 1982;54:254–60.
104. Sparrow D, Borkan GA, Gerzof SG, Wisniewski C, Silbert CK. Relationship of fat distribution to glucose tolerance. Results of computed tomography in male participants of the Normative Aging Study. *Diabetes* 1986;35:411–5.
105. Bjorntorp P. Adipose distribution, plasma insulin, and cardiovascular disease. *Diabetes Metab* 1987;13:381–5.
106. Despres JP, Nadeau A, Tremblay A, Ferland M, Lupien PJ. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. *Diabetes* 1989;38:304–9.
107. Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. *Diabetes* 1992;41:826–34.
108. Kissebah AH, Krakower GR. Regional adiposity and morbidity. *Physiol Rev* 1994;74:761–811.
109. Gautier JF, Milner MR, Elam E, Chen K, Ravussin E, Pratley RE. Visceral adipose tissue is not increased in Pima Indians compared with equally obese Caucasians and is not related to insulin action or secretion. *Diabetologia* 1999;42:28–34.
110. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? *Diabetes Care* 2003;26:2556–61.
111. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fat distribution. *Diabetes* 1990;39:283–99.
112. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. *Am J Clin Nutr* 2005;81:555–63.
113. Seidell JC, Cigolini M, Deslypere JP, Charzewska J, Ellsinger BM, Cruz A. Body fat distribution in relation to serum lipids and blood pressure in 38-year-old European men: the European fat distribution study. *Atherosclerosis* 1991;86:251–60.
114. Folsom AR, Li Y, Pao X, et al. Body mass, fat distribution and cardiovascular risk factors in a lean population of south China. *J Clin Epidemiol* 1994;47:173–81.
115. Sakurai Y, Kono S, Shinchi K, et al. Relation of waist-hip ratio to glucose tolerance, blood pressure, and serum lipids in middle-aged Japanese males. *Int J Obes Relat Metab Disord* 1995;19:632–7.
116. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans. *Diabetes Care* 1996;19:414–8.
117. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes. *Circulation* 2005;112:3066–72.
118. Standards of medical care in diabetes. *Diabetes Care* 2004;27(suppl):S15–35.
119. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005;28:2289–304.

